Ryoncil Net Revenue for the Quarter Increases to US$30.3M
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallIn the deck
Earlier from Mesoblast
- Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
- Mesoblast to Host R&D Day on April 8, 2026
- Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast
- Ryoncil Profits Underpinning Substantial Growth Pipeline
- Corporate Presentation and Half Year Financial Results
Later from Mesoblast
- Mesoblast R&D Day Features Significant Commercial Progress & Platform Innovation
- Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy - CORRECTION
- Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products
- Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
- Patient Recruitment Target Achieved in CLBP Pivotal Trial
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast